Page 18 - ebook

고형암 항암치료 환자의 부작용 관리 Nausea and Vomiting

Classification Agent

Parenteral Minimal emetic risk Nivolumab
Obinutuzumab
Ofatumumab
Panitumumab
Pegaspargase
Pembrolizumab
Pertuzumab
Ramucirumab
Rituximab
Siltuximab
Temsirolimus
Trastuzumab
Vinblastine
Vincrristine
Vinorelbine
Oral High-moderate Altretamine
emetic risk Avapritinib
Azacytidine
Binmetinib
Bosutinib >400 mg/day
Busulfan ≥ 4 mg/day
Capmatinib
Ceritinib
Crizotinib
Cyclophosphamide ≥ 100 mg/m /day
2
Dabrafenib
Enasidenib
Encorafenib
Estramustine
Etoposide
Fedratinib
Imatinib >400 mg/day
Levatinib > 12 mg/day
Lomustine (single day)
Midostaurin
Mitotane
Niraparib
Ofaparib
Procarbazine
Rucaparib
Selinexor
2
Temozolomide > 75 mg/m /day

18